翰森制药(3692.HK)：上半年总收入74.34亿元同比增长14.3%，创新药收入占比82.7%

Core Insights - Hansoh Pharmaceutical (3692.HK) reported total revenue of approximately 7.434 billion RMB for the first half of 2025, representing a year-on-year growth of about 14.3% [1] - The company's profit reached approximately 3.135 billion RMB, with a year-on-year increase of about 15.0% [1] - Basic earnings per share were approximately 0.53 RMB, reflecting a year-on-year growth of about 14.8%, and an interim dividend of 0.2316 HKD per share was declared, showcasing strong profitability and shareholder returns [1] Revenue Breakdown - Sales revenue from innovative drugs and collaborative products amounted to approximately 6.145 billion RMB, marking a year-on-year growth of about 22.1% and accounting for 82.7% of total revenue [1] Financial Performance - The net cash inflow from operating activities for the first half of 2025 was 3.605 billion RMB [1] - As of June 30, 2025, the company had cash and bank deposits totaling 27.104 billion RMB, indicating a robust financial position and strong cash flow to support future innovation and R&D investments [1]